Bacterial infections are an important complication of cirrhosis, particularly in hospitalized patients. In this article we review the prevalence, risk factors, and pathogenesis of bacterial infections in cirrhosis, focusing on the mechanisms of bacterial translocation such as impaired immunity and bacterial overgrowth, as well as maneuvers that may inhibit bacterial translocation and could be used not only to prevent infections but also to ameliorate the hyperdynamic circulatory state of cirrhosis. We also review the clinical features and management of the most common infection in cirrhosis, spontaneous bacterial peritonitis (SBP), specifically the evidence behind the therapy of acute SBP, the role of albumin, and the role of antibiotics in the prophylaxis of high-risk patients. It has been recognized that SBP and other bacterial infections lead to the systemic inflammatory response syndrome, sepsis, and multiorgan failure. We review the pathogenesis and management of these complications, the role of adrenal insufficiency, and the utility of intensive care prognostic models.
Bacterial infections account for significant morbidity and mortality in patients with cirrhosis, particularly in hospitalized patients. Patients with cirrhosis are predisposed to infection due to an impaired immune function together with an increased passage of bacteria from the gut (bacterial translocation [BT] ) that is in turn facilitated by altered intestinal immunity and bacterial overgrowth. BT (without overt infection) contributes to a worsening in the hemodynamic status of advanced cirrhosis. Once an overt infection occurs, it may lead to systemic inflammatory response syndrome (SIRS)/sepsis which can precipitate hypotension (severe sepsis), renal dysfunction, encephalopathy, and coagulopathy, that is, multiorgan failure. With further deterioration in the hemodynamic status, septic shock and death will ensue in the cirrhotic patient. Although the most common bacterial infection in this population is spontaneous bacterial peritonitis (SBP), other sources of infection can also lead to sepsis and multiorgan failure. Prophylaxis, early recognition, and rapid management of bacterial infections and their complications are essential to improve patients' survival.
BACTERIAL INFECTIONS IN CIRRHOSIS

Prevalence and Risk Factors
Bacterial infections occur in 32 to 34% 1,2 of hospitalized patients with cirrhosis and in $45% of those admitted with gastrointestinal (GI) hemorrhage 3 (Table 1 ). This infection rate is much higher than the 5 to 7% infection rate reported in the general population of hospitalized patients. In addition, cirrhotic patients have a higher relative risk of dying from sepsis than noncirrhotic patients. 4 The most common bacterial infections are SBP (25%), urinary tract infections (UTI) (20%), pneumonia (15%), and bacteremia (12%). 2 GI hemorrhage and the severity of liver disease, as reflected by the serum albumin 5 and the ChildTurcotte-Pugh (CTP) score, 6, 7 are independent predictors of bacterial infections in patients with cirrhosis. As shown in Table 1 , the rate of infection in cirrhotic patients admitted with GI hemorrhage not placed on antibiotic prophylaxis is 44%, with rates as high as 67% in series including a larger percentage of patients with ascites or CTP-C and with the most common infections being SBP or spontaneous bacteremia. [8] [9] [10] [11] [12] [13] [14] Pathogenesis
IMMUNE DYSFUNCTION
The increased rate of bacterial infections in cirrhotic patients is mostly due to an associated immunocompromised state. Immune dysfunction in the cirrhotic patient is multifactorial 15, 16 and is partly due to a decrease in bactericidal activity by phagocytic cells. [17] [18] [19] [20] Additionally, complement levels, which are critical in bacterial phagocytosis, are low in cirrhosis, [21] [22] [23] mainly in cirrhosis with ascites 22 and in patients with liver insufficiency. 21, 23 Importantly, cirrhosis is accompanied by an impaired reticuloendothelial system (RES), the main defensive system against bacteremia and other infections acquired through a hematogenous route. Most of the RES activity is located in the liver where Kupffer's cells (tissue macrophages) are the major components. In cirrhosis, RES activity is impaired because of portosystemic shunting that bypasses the liver (thereby escaping the action of the RES) and because of impaired Kupffer's cell phagocytic activity. Patients with a decreased RES activity develop spontaneous bacteremia and SBP at a higher rate than patients with a normal RES. 24 Bypassing the RES through portosystemic shunting is not only an important mechanism that explains failure to clear portal or systemic bacteria in cirrhosis, but it also explains failure to clear other bacterial products such as endotoxins and cytokines. The even higher risk of infection in cirrhotic patients with GI hemorrhage is thought to be secondary to multiple factors, among them a further decrease in RES activity 25, 26 and a higher rate of BT. 27 
BT IN CIRRHOSIS
In cirrhosis, enteric gram-negative bacteria (mostly Escherichia coli) are more commonly isolated in SBP 2, 28 and in UTI, 2 while gram-positive bacteria are more likely to be the causative agent in cases of pneumonia *Untreated or placebo-treated control group of a randomized study.
CTP-C, Child-Turcotte-Pugh-C; NS, not stated; SBP, spontaneous bacterial peritonitis; UTI, urinary tract infection.
(Streptococcus) and instrumentation-related infection (Staphylococcus). 2 Although the relative importance of gram-positive pathogens increases in the setting of norfloxacin prophylaxis and invasive procedures, 2 gut bacteria play an important role not only in the genesis of overt gram-negative or enterococcal infections but, as shown below, also in the hemodynamic status of the cirrhotic patient (Fig. 1) .
BT refers to the migration of bacteria or bacterial products (lipopolysaccharides [LPS], endotoxins) from the lumen of the intestine to extraintestinal sites such as the mesenteric lymph nodes (MLN). 29 Although passage of commensal bacteria to MLN is a normal process that results in bacterial destruction, 30 BT can become clinically significant with a failure of local/systemic immune defense mechanisms as occurs in cirrhosis. 31, 32 BT to MLN occurs in $50% of cirrhotic rats with ascites (but does not occur in cirrhotic animals without ascites) 32 and has been implicated in the exacerbation of the baseline hyperdynamic circulatory state of the cirrhotic patient (in the absence of infection) as well as in the development of spontaneous infections in cirrhotic patients (Fig. 1) . The hyperdynamic circulatory state of cirrhosis is characterized by splanchnic and systemic vasodilation, increased cardiac output, and decreased mean arterial pressure. It is responsible for variceal growth, ascites, and the hepatorenal syndrome (HRS). BT of bacteria and bacterial products leads to activation of monocytes and lymphocytes and increased serum levels of proinflammatory cytokines such as tumor necrosis factor-a (TNF-a) with the subsequent activation of nitric oxide (NO) in the splanchnic and systemic circulation, leading to vasodilation (Fig. 1) . The gut origin of the inflammatory cascade and the direct influence on the splanchnic circulation are supported by higher portal vein than systemic vein levels of NO 33 and endotoxin 34 in cirrhotic patients. The link between BT and the hyperdynamic circulatory state is supported by the finding of a more significant hemodynamic impairment (lower mean arterial pressure, vasoconstrictor hyporesponsiveness) in cirrhotic ascitic rats with BT compared with those without BT. 35 BT is associated with local and systemic endotoxemia and increases in NO levels, thereby leading to aggravation of vasodilation. 36 This relationship is supported by studies in patients with cirrhosis showing an amelioration of the hyperdynamic circulation through selective intestinal decontamination using poorly absorbed antibiotics. [37] [38] [39] Figure 1 Mechanisms in the development of bacterial infections, sepsis, and multiorgan failure in cirrhosis. In advanced cirrhosis (with ascites) there is increased translocation of bacteria and bacterial products from the gut that leads to worsening of the hyperdynamic circulation that is responsible for many of the complications of cirrhosis such as variceal growth, variceal hemorrhage, and ascites (green). On the other hand (purple), bacterial translocation plays an important role in the pathogenesis of infections (particularly gram-negative), but sources other than the gut are of increasing importance. Infections lead to SIRS/ sepsis and, as further vasodilation occurs, this can lead to septic shock and/or multiorgan failure and death. About half the patients with SIRS/sepsis have relative adrenal insufficiency and this is a factor predictive of multiorgan failure and death. *Hypotension and organ failure still responding to intravascular volume loading ¼ severe sepsis. **Septic shock ¼ hypotension refractory to adequate restoration of intravascular volume, when associated with perfusion abnormalities and requiring the use of inotropes. SIRS, systemic inflammatory response syndrome.
BT to MLN has been detected in up to 80% of animals with infected ascitic fluid. 32, 40 Evidence supporting the role of BT in SBP shows that organisms identified in MLN are identical to those found in ascitic fluid. 41 Similarly, bacteria that translocate most readily are those more commonly implicated in the infectious complications of cirrhosis, for example, gram-negative Enterobacteriaceae (E. coli and Klebsiella pneumoniae), enterococci, and streptococci, 42,43 while anaerobic bacteria that rarely translocate 42,44 are responsible for < 1% of bacterial infections in cirrhosis.
SURROGATE MARKERS OF BT IN HUMANS
Studies of BT in humans show that BT to MLN occurs in cirrhosis, particularly in those with the most severe disease 45 ; however, these studies are performed in patients subjected to laparotomy and inherent methodological difficulties may have led to discrepant findings between animals and humans. 46 Recently, surrogate markers of BT have been proposed. One of them is the serum lipopolysaccharide binding protein (LBP), a protein with a relatively long half-life synthesized by the liver in response to bacteremia or endotoxemia. Patients with abnormally elevated LBP levels have been shown to have a lower mean arterial pressure, lower systemic vascular resistance and the most marked activation of compensatory hormones (renin, aldosterone), proinflammatory cytokines (TNF-a, interleukin-[IL-] 6) and NO levels. 39 Interestingly, a prospective study in uninfected patients with cirrhosis and ascites shows that patients with an elevated LBP (> 9.6 mg/mL) are 4 times more likely to develop a bacterial infection than those with normal LBP (32% versus 8% in 46 weeks). 47 The detection of bacterial DNA (bDNA) in biological fluids is another potential marker of BT. In experimental cirrhosis, the detection of bDNA in serum, ascites, or pleural fluid is always coupled with bDNA in MLN and is associated with increased serum TNF-a, IL-6, and NO levels, even in the absence of positive MLN bacteriological cultures. 48 In humans, bDNA in ascites and serum is present in about a third of patients with cirrhosis and ascites. 49 It is related to marked activation of peritoneal macrophages, as evidenced by enhanced cytokine and NO production 50 as well as complement activation indistinguishable from that observed in patients with SBP. 51 In fact, patients with cirrhosis and ascites and positive bDNA appear to have more hemodynamic alterations than those without bDNA.
52
MECHANISMS OF BT
Several factors contribute to BT including intestinal bacterial overgrowth, increased intestinal permeability, and immune dysfunction.
Intestinal Bacterial Overgrowth (IBO) IBO is an important factor promoting BT. 15 IBO, determined by hydrogen breath tests, is more common in cirrhotic patients than in controls, especially in those with CTP B/C disease 53 or a previous history of SBP. 54 Delayed small bowel transit, a major factor implicated in the pathogenesis of IBO, is more common in patients with cirrhosis as compared with controls and improves after liver transplantation. 55, 56 Disordered small bowel motility (lack of cyclic activity, abnormal clustering of contractions) is more common in CTP class B/C compared with CTP-A patients. 57 The impaired motility has been attributed to excess adrenergic and NO stimulation as well as structural damage to the intestine from oxidative damage and portal hypertension. [58] [59] [60] In one study, IBO was found to be an independent risk factor for endotoxemia in cirrhotic patients. 61 While BT rarely occurs in the absence of IBO, only about half the experimental animals with IBO demonstrate BT, 62 indicating that other mechanisms must be associated with IBO for BT to occur.
Increased Intestinal Permeability The structural alterations in cirrhotic patients (vascular congestion, edema, widened intracellular spaces, inflammation) may predispose to an increase in intestinal permeability. 43, 63 This is likely multifactorial, related to oxidative damage, endotoxemia, and an increase in the synthesis of cytokines and NO. 43 Although animal studies have demonstrated an increase in intestinal permeability in cirrhosis, 62, 64 studies in humans have yielded conflicting results.
65-68
Decreased Immunity For BT to become clinically significant, that is, for it to lead to SBP or bacteremia, a failure of local and systemic immune defenses should also be present. In a healthy, nonimmunocompromised host, translocated bacteria may reach MLN or portal blood but they will usually be phagocytosed and killed prior to multiplication and seeding of systemic blood and other sites. Although mononuclear cells recognize the presence of bacteria, the innate immune system response in cirrhotic patients is impaired due to a reduction in phagocytosis, opsonization capacity, and complement levels. Furthermore, impairment in the adaptive immune response such as reduced numbers and impaired activation of T-cells 69 and a reduction in IgA levels 70 may play a role in the spread of intestinal bacteria to extraintestinal sites.
MEASURES TO DECREASE BT
Inhibition of BT can be achieved by (1) eliminating gram-negative organisms from the gut through the oral administration of nonabsorbable or poorly absorbed antibiotics, the so-called ''selective intestinal decontamination'' (SID), (2) by changing the composition of gut bacterial flora through the administration of pre/probiotics or bile acids; and (3) by accelerating intestinal transit (thereby decreasing IBO) through the use of prokinetics or b-blockers. A decrease in infections or amelioration of the hyperdynamic circulatory state with these measures is proof of concept of the role of BT in their pathogenesis.
Norfloxacin and Other Poorly Absorbed Antibiotics Although animal studies have yielded conflicting data about the impact of SID on BT, 27, 38, 71, 72 in patients with cirrhosis, SID with norfloxacin has significantly reduced the rates of SBP and other bacterial infections in different settings: GI hemorrhage, 3, 9, 73 prevention of SBP recurrence, 74 and prevention of first SBP. 75 Prebiotics/Probiotics Probiotics are an integral part of the normal intestinal flora that may provide benefit by immune modulation, reducing inflammatory cytokines, tightening the intestinal barrier, and altering the intestinal microflora by suppressing the growth, glycosylation, epithelial binding, and invasion of pathogenic bacteria. 76 In the post-transplant setting, randomized controlled trials using combinations of lactic acid bacteria and fermentable fiber reduced the postoperative infection rate from 48% to between 3% and 13%. 77, 78 However, reduction of BT in animal models of cirrhosis has not been uniform [79] [80] [81] [82] and caution must also be exercised, as case reports of Lactobacillus sepsis attributed to probiotic therapy have been reported. 83, 84 Prokinetics Reductions in intestinal transit time, bacterial overgrowth, and BT have been noted with cisapride therapy in experimental animals. 64, 85 In patients with cirrhosis, cisapride is effective in reducing IBO but without a significant effect on the development of bacterial infections. 85, 86 Only one study showed a benefit of a combination of norfloxacin and cisapride versus norfloxacin in patients with cirrhosis and a low ascitic fluid protein or a previous history of SBP. 87 The very high rate of SBP in patients receiving norfloxacin prophylaxis (57% at 1 year) in this study makes the results difficult to interpret. 87 b-Adrenergic Blockers Adrenergic stimulation is purportedly the primary factor in slowing intestinal motility in cirrhosis. In fact, propranolol shortens intestinal transit time and reduces bacterial overgrowth and BT in rats. 62 In a retrospective study, patients with SBP were less likely to be on nonselective b-blockers for the prophylaxis of variceal hemorrhage 88 but there is no definitive evidence that b-blockers reduce the development of SBP. Interestingly, pharmacologically induced reductions in portal pressure (as determined by the hepatic venous pressure gradient) have been associated with reductions in the development of SBP. [89] [90] [91] Figure 2 Approach to the patient with suspected SBP. *A diagnostic paracentesis should be performed in any patient with symptoms or signs suggestive of SBP, any patient with unexplained renal dysfunction or encephalopathy, and in any hospitalized patient with cirrhosis and ascites. An ascites PMN count > 250/mm 3 is diagnostic of SBP and should be followed by therapy with I.V. antibiotics (cefotaxime, ceftriaxone, or amoxicillin/clavulanic acid). In the presence of high-risk factors for renal dysfunction (bilirubin > 4 mg/dL, creatinine > 1 g/dL), albumin should be administered at a dose of 1.5 g/Kg on the first day, and 1.0 g/Kg on the third day, although this dose is arbitrary and should be limited to a maximum of 100 g. With obvious clinical improvement or a decrease in ascites PMN at day 2, I.V. antibiotics can be switched to oral for an additional 3 to 5 days, followed by norfloxacin prophylaxis (400 mg every day). SBP, spontaneous bacterial peritonitis; PMN, polymorphonuclear; I.V., intravenous.
Bile Acids In addition to their role in digestion, bile acids affect the microflora and integrity of the small intestine. Obstruction of bile flow in humans or rodents causes proliferation of intestinal bacteria and mucosal injury, which can lead to BT. 92 In cirrhosis, marked decreases in intestinal intraluminal concentrations of bile acids have been ascribed to decreased secretion and increased deconjugation by enteric bacteria. The oral administration of conjugated bile acids, such as cholylsarcosine and cholylglycine in ascitic cirrhotic rats, results in a reduction in bacterial overgrowth, BT, and endotoxemia and an increase in survival. 93 
Spontaneous Infections in Cirrhosis DEFINITION
The most common infections in cirrhosis and those considered characteristic of the disease are the so-called ''spontaneous'' infections, namely SBP, spontaneous bacterial empyema, and spontaneous bacteremia, which share pathogenic mechanism and management. They are called spontaneous because there is no obvious source of bacteria that would explain their spread to ascites, pleural fluid, or blood, respectively. However, and as recently reviewed, 16 cirrhotic patients are at risk for other common and uncommon bacterial infections due to their immunocompromised state. Although the data in this area are limited, it is clear that CTP-C patients are at the highest risk for infection. 16 Further evaluation of nonspontaneous bacterial infections and the role of preventive measures such as vaccination is required.
DIAGNOSIS
The clinical presentation of SBP can range from a lack of symptoms to abdominal pain, fever, and GI symptoms or end-organ dysfunction (renal insufficiency, encephalopathy, hemodynamic instability). 94 With the high rate of asymptomatic SBP ($50%) in hospitalized patients and significant adverse consequences with missed infection, a diagnostic paracentesis is recommended at admission and in patients who present any symptom, sign, or laboratory value suggestive of SBP. 24 The diagnostic and management strategy in patients with suspected SBP is depicted in Fig. 2 . The diagnosis of SBP is made when the ascitic fluid polymorphonuclear (PMN) count is > 250/mm 3 . It has been suggested that a faster, inexpensive method of making the diagnosis of SBP is through the use of reagent strips; however a recent review shows that the false-negative rate ranges between 0 and 50% 95 and in the largest series of patients with SBP, using the Multistix 6G (Bayer Pharma SAS, Puteaux, France), the false negative rate was 55%. 96 Therefore, the use of reagent strips cannot be recommended.
Ascitic fluid cultures (10 mL into a blood culture bottle) and blood cultures should also be obtained with the suspicion of SBP, as 50% of SBP cases are associated with bacteremia 97 and identifying an infecting organism will facilitate therapy.
Distinguishing between primary and secondary peritonitis is essential as the latter almost always requires surgical management. Secondary peritonitis should be suspected in the setting of a polymicrobial ascitic fluid culture, isolation of anaerobes or fungi, or an inadequate clinical or ascitic fluid cell count response with standard antibiotic therapy.
TREATMENT
When first described, the mortality of SBP exceeded 90%; however, with early recognition of the disease and prompt and appropriate antibiotic therapy, mortality has been reduced to around 15 to 20%. 98 Since renal insufficiency is the most important predictor of mortality in SBP, large volume paracentesis, diuretic therapy, and nephrotoxins should be avoided during acute infection.
Antibiotics The third generation cephalosporins (cefotaxime, ceftriaxone) are the agents of choice in the treatment of SBP. The most cost-effective dose of cefotaxime is 2 g intravenously (I.V.) every 12 hours. 99 Ceftriaxone is recommended at a dose of 1 g I.V. every 12 to 24 hours. Amoxicillin/clavulanate has been compared with I.V. cefotaxime with similar results. 100 Although a subgroup of patients with ''uncomplicated'' SBP (absence of all of the following: septic shock, grade 2 to 4 hepatic encephalopathy (HE), ileus, GI hemorrhage, or creatinine > 3 g/dL) may be treated with oral highly bioavailable quinolones such as ofloxacin, 100 their use will depend on the local prevalence of quinoloneresistant microorganisms. 101 Although a minimum of 5 days of therapy has been suggested by the consensus guidelines, 94 8 days may be a more conservative treatment duration as it represents the median time for SBP resolution in clinical trials. 95 Importantly, I.V. antibiotics can be switched to oral in 48 hours if there is clinical improvement and/or ascites PMN shows a significant improvement.
Albumin Albumin improves cirrhotic hemodynamics by various mechanisms. In addition to plasma expansion and an increase in the cardiac preload, it binds vasodilating substances and cytokines and has an antioxidant effect. 102, 103 Infections can lead to further derangement in the hemodynamic status of the patient with cirrhosis and can lead to renal dysfunction. Albumin, as an adjuvant to antibiotic therapy, has been shown to significantly reduce the rate of renal dysfunction, inhospital mortality, and overall mortality. 104 Albumin has been administered at an arbitrary dose of 1.5 g/Kg body weight I.V. at diagnosis and 1 g/Kg body weight I.V. on day 3 of therapy but the optimal dose is unknown. Renal impairment occurs in < 10% of patients when serum bilirubin is < 4 mg/dL and serum creatinine is < 1 mg/ dL. 104, 105 As albumin is an expensive blood product with associated risks, its use should be limited to high-risk patients (bilirubin > 4 mg/dL, creatinine > 1 mg/dL) with SBP.
PROPHYLAXIS
Until nonantibiotic measures to prevent infection are tested clinically, prophylaxis is based on SID, mainly through the use of oral norfloxacin. However, this therapy is associated with quinolone and trimethoprimsulfamethoxazole resistance 2 and thus patients in whom prophylaxis is prescribed should be carefully selected and restricted to those at the highest risk of SBP.
Hospitalized Patients with GI Hemorrhage There is a clear benefit of short-term (5 to 7 days) antibiotic prophylaxis in cirrhotic patients presenting with a GI hemorrhage. A meta-analysis of five studies demonstrated a reduction in infection (45% versus 14%) and mortality (24% versus 15%) when prophylactic antibiotics are administered at admission compared with administration of antibiotics only in the presence of infection. In this meta-analysis, no difference was identified between oral versus I.V. antibiotics. 3 A recent randomized controlled trial compared I.V. ceftriaxone (1 g/day) versus oral norfloxacin (400 mg twice a day) in patients with ''advanced'' cirrhosis (at least two of: ascites, severe malnutrition, encephalopathy, or bilirubin > 3 mg/dL) and upper GI hemorrhage (any source). 106 Although there were fewer patients with proven or possible infections on ceftriaxone (11% versus 33%), the end point of SBP or spontaneous bacteremia was not significantly different (12% of patients on norfloxacin versus 2% of patients on ceftriaxone). Moreover, there were no significant differences in mortality. It is uncertain whether the benefit of ceftriaxone was due to its I.V. administration or whether the lower efficacy of norfloxacin was due to norfloxacin-resistance. Additionally, only 9% of the patients met entry criteria and therefore the results are not widely applicable. 106 Therefore, I.V. ceftriaxone is a reasonable option in patients with ''advanced'' cirrhosis and upper GI hemorrhage.
Patients with an Ascites Protein < 1 g/dL Patients with low ascitic protein levels (< 1 g/dL) are at an increased risk of SBP (20% at 1 year versus 0% at 1 year if ascitic protein > 1 g/dL). 107 Previously published studies have been inconclusive regarding the benefit of antibiotic therapy. [108] [109] [110] [111] However, a recent placebo-controlled study that included patients with low (< 1.5 g/dL) ascites protein who also had advanced liver failure (CTP score ! 9 and serum bilirubin ! 3 mg/dL) or renal dysfunction (serum creatinine ! 1.2 mg/dL, blood urea nitrogen level ! 25 mg/dL, or serum sodium level 130 mEq/L) demonstrated a reduction in the 1 year probability of SBP (7% versus 61%), HRS (28% versus 41%), and 3-month mortality. 75 Notably, all patients were initially hospitalized, less than half of them met entry criteria and the survival benefit did not extend to 1 year.
Patients Who Have Recovered from an Episode of SBP These patients have a 1-year probability of recurrent SBP of 70% and a 1-year survival of 30 to 50%. 74, 112 A placebo-controlled trial demonstrates a significant reduction in SBP recurrence at 1 year with norfloxacin 400 mg once daily (20% versus 68%). 74 The study of once-weekly ciprofloxacin was limited by the inclusion of patients with and without a preceding history of SBP. 108 Considering this major limitation, increased rates of quinolone resistance, and lower efficacy on this regimen, daily therapy is considered superior to once-weekly therapy 113, 114 and is indicated in the secondary prophylaxis of SBP (Fig. 2) .
SIRS AND SEPSIS IN CIRRHOSIS
Definitions SIRS is defined as two or more of the following: temperature > 388 C or < 368 C; heart rate > 90 beats per minute; respiratory rate > 20 breaths per minute or PaCO 2 < 4.3 kPa; white cell count > 12 Â 10 9 /L or < 4 Â 10 9 /L, or the presence of > 10% immature neutrophils. Sepsis refers to SIRS associated with a confirmed bacterial infection (i.e., positive bacteriological culture). Severe sepsis represents a more marked imbalance as a result of infection, with evidence of organ dysfunction, hypoperfusion, or hypotension that responds to intravascular volume loading alone. Septic shock is sepsis associated with hypotension refractory to intravascular volume loading, associated with perfusion abnormalities, and requiring the use of inotropes. 115 
Pathogenesis
Cirrhosis is an independent risk factor for sepsis and moreover for a poor outcome in the setting of sepsis. 1, 4, [116] [117] [118] The development of SIRS in patients with cirrhosis has been associated with the development of ''acute-on-chronic liver failure,'' an entity recently defined as an acute (within 2 weeks) deterioration of liver function (encephalopathy or HRS and a bilirubin > 5 mg/dL) with an increased mortality. 119 In cirrhosis, SIRS is most commonly initiated by bacterial infections. As recently reviewed, 120 bacteria and bacterial products activate various mechanisms to cause tissue injury and organ failure, including cytokine production such as TNF-a, IL-6, and IL-1, which initiate and propagate the inflammatory response, as well as circulatory alterations and changes in the coagulation cascade. The pathophysiology of the exaggerated systemic response to infection in cirrhosis has been proposed to stem from BT and a baseline release of bacterial products (endotoxins, proteases, LPS, peptidoglycans). As mentioned previously, endotoxin levels are increased in patients with cirrhosis and increase with progressive hepatic dysfunction. 121, 122 These products stimulate the release of NO and inflammatory cytokines (TNF-a, IL-1, IL-6, and IL-12) . 123, 124 NO is a critical mediator in the SIRS response, its levels increasing with worsening hepatic function. The metabolites of NO play a role in the formation of reactive oxygen species and resulting cellular necrosis as well as in the inhibition of platelet aggregation. 123, 125 The effects of NO on the smooth muscle and endothelial cells can result in refractory hypotension. 120 Anti-inflammatory cytokines (IL-10, IL-4, IL-13, prostaglandin E2) are unable to balance the effects of the proinflammatory mediators and a more pronounced response to bacterial infection occurs as compared with controls. 123, 124, [126] [127] [128] The exaggerated response to infection in cirrhotic patients may also be attributed to a reduction in ''protective'' (anti-inflammatory) factors such as activated protein C and high-density lipoprotein. In fact, a study performed in experimental cirrhotic animals shows that the administration of high-density lipoprotein attenuates the increased effect of endotoxin on cytokine production and on systemic hemodynamics in cirrhosis. 124 More recent data point to the concept of ''immune paralysis'' in patients with decompensated cirrhosis. Immune paralysis is an established entity defined as a reduction in monocyte human leukocyte antigen-DR (HLA-DR) expression and therefore an impairment in LPS-stimulated proinflammatory cytokine production (IL-1, IL-6, IL-8, TNF-a). 121, 129 The correlation of immune paralysis with the severity of sepsis has been well established. 130, 131 A reduction in HLA-DR expression and ex-vivo TNF-a production has been reported in acute-on-chronic liver failure patients 132 and in CTP-C patients. 133 The pathogenesis of this entity is not completely understood. Although a concurrent increase in the anti-inflammatory cytokine IL-10 has been described in the setting of monocyte deactivation, it is unclear whether it plays a role in the reduction of HLA-DR expression. 129, 133, 134 Multiorgan Failure As shown in Fig. 1 , the above-mentioned alterations can lead to refractory hypotension, renal dysfunction, encephalopathy, coagulopathy, and other complications. As for noncirrhotic patients, there is a clear association between the number of failing organ systems and mortality in cirrhosis. 135 
CIRCULATORY ABNORMALITIES, SEVERE SEPSIS, AND SEPTIC SHOCK
It has been suggested that the diagnosis of SIRS, sepsis, or severe sepsis may be difficult in a patient with advanced cirrhosis because of baseline hypotension secondary to the hyperdynamic circulatory state, a reduction in neutrophil counts secondary to hypersplenism, and an elevated respiratory rate due to HE. 120 As mentioned above, the hemodynamic alterations typical of cirrhosis (splanchnic and peripheral vasodilation) are exaggerated in patients with cirrhosis and infection. A study that analyzed patients with septic shock admitted to an intensive care unit (ICU) showed that patients with cirrhosis had a higher cardiac index (i.e., they were more hyperdynamic), higher plasma lactate concentrations, lower temperature, and a higher mortality rate compared with patients without cirrhosis. 136 
RENAL FAILURE
Renal dysfunction develops in 33% of patients with SBP despite the resolution of infection with antibiotic therapy. 104, 137 Renal failure in the setting of ongoing bacterial infection, but in the absence of septic shock, was recently considered diagnostic of HRS. 138 The pathogenesis of renal dysfunction in the setting of infection is related to worsening splanchnic and systemic vasodilation leading to a further decrease in effective arterial blood volume, with the consequent activation of neurohumoral systems (renin-angiotensin-aldosterone) that leads to renal vasoconstriction and renal dysfunction. A prospective study performed in patients with SBP shows that, in those who develop renal failure, mean arterial pressure is lower and plasma renin, aldosterone, and norepinephrine concentrations are higher. 102 Interestingly, patients with renal failure had a lower baseline cardiac output and this was attributed in part to cirrhotic cardiomyopathy. 139 The increases in renin and aldosterone in patients with SBP-related renal failure have been clearly associated with increases in inflammatory cytokines (TNF, IL-6) and vasodilatory hormones (NO). 140, 141 The administration of albumin results in a reduction in renal impairment and reduced inhospital mortality. 104 Two recent prospective studies extend the findings of renal dysfunction precipitated by SBP alone to include other bacterial infections. 142, 143 Similar to SBP, non-SBP infections are associated with impairment of the effective circulating volume and precipitate renal failure in approximately one third of cirrhotic patients. 142 The inclusion of the creatinine in the MELD score reflects the importance of renal failure as a key determinant of mortality in patients with cirrhosis.
142,143
INFECTIONS, SEPSIS, AND MULTIORGAN FAILURE/TANDON, GARCIA-TSAO
The risk of death increases with the severity of renal dysfunction.
138,144
ENCEPHALOPATHY
Infection is a well-recognized precipitant of HE. Evidence suggests that SIRS leads to progression of HE in both acute and acute-on-chronic liver failure. 145 In patients with cirrhosis and infection (but without overt HE), induced hyperammonemia results in a significant deterioration of neuropsychological test scores in patients with evidence of SIRS, but not after its resolution, suggesting that SIRS mediators, such as NO and proinflammatory cytokines, may be important in modulating the cerebral effect of ammonia in cirrhosis. 146 This ''sepsis-associated encephalopathy'' has been linked to the production of reactive oxygen species, the direct effect of inflammatory cytokines on cerebral endothelial cells, astrocytes and vagal afferents, and a reduction in cerebral blood flow. 147 To further support this, injection of LPS into cirrhotic rats induces precoma and exacerbates cytotoxic edema because of a synergistic effect of hyperammonemia and the induced inflammatory response. 148 
COAGULOPATHY
Coagulation abnormalities in cirrhosis are attributed to a reduction in the hepatic synthesis of factors VII, V, X and prothrombin, vitamin K deficiency, and quantitative and qualitative platelet defects. Coagulation abnormalities are greater in cirrhotic patients with sepsis, 149 perhaps as a result of more severe liver dysfunction. Furthermore, the release of cytokines (IL-1, IL-6, TNF-a) with sepsis impairs platelet function, increases fibrinolysis, the consumption of clotting factors, 149, 150 and the production of endogenous heparin-like substances. 151 Bacterial infections are common in cirrhotic patients with variceal hemorrhage (Table 1) . Conversely, the presence of infection may precipitate variceal hemorrhage by increasing portal pressure and altering hemostasis, 152 thereby increasing mortality. Prophylactic antibiotics in this setting decrease infections, 3 rebleeding, 153 and mortality. 3 
ACUTE RESPIRATORY DISTRESS SYNDROME
Acute respiratory distress (ARDS) refers to hypoxia and bilateral radiographic infiltrates in the absence of an elevated left atrial pressure. 154 Several studies have suggested that cirrhosis is an independent predictor of mortality in a patient who develops ARDS. 155, 156 As per the other complications, the association between cirrhosis and ARDS has been linked to an increase in serum cytokines, NO, and pulmonary leukotrienes.
157,158
DEATH
Once infection develops, renal failure, shock, and encephalopathy may follow, which adversely affect survival. The in-hospital mortality of cirrhotic patients with infection is $15%, more than twice that of patients without infection. 120 Infection is directly responsible for $30% of deaths in cirrhosis (Table 1 ). In the presence of renal dysfunction the incidence of mortality with SBP increases to 42%. 137 Independent predictors of in-hospital mortality after SBP were identified in a recent review. 95 Renal dysfunction, as identified by serum creatinine or blood urea nitrogen elevation, was the most common independent baseline predictor of death. 95 In studies of cirrhotic patients admitted to a medical ICU, the Acute Physiology and Chronic Health Evaluation (APACHE) III score (described below), the use of pressors, acute renal failure, and coma have been noted as independent predictors of in-hospital mortality. 135, 159 Prognostic Models for Cirrhotic Patients Admitted to the ICU An accurate assessment of prognosis is essential for determining individual patient outcomes, for making therapeutic decisions, and, in the case of critically ill patients, for determining when ICU support is futile. Various scoring systems have been proposed but few have been validated prospectively in patients with cirrhosis and SIRS/sepsis.
Both liver-specific models such as MELD score, 160 CTP score, 161 and general prognostic models such as the APACHE II and III, 162, 163 the organ system failure (OSF), 164 and the sequential organ failure assessment (SOFA) 165 have been used for assessing outcome in critically ill cirrhotic patients. The OSF score is based on the number of organ systems that have failed (respiratory, coagulation, liver, cardiovascular, central nervous system, renal) whereas the SOFA score allows for scoring based on the degree of dysfunction in each organ system. 166 A systematic review of 21 prognostic studies determined that general models were superior to the CTP Score. 167 In-hospital mortality was high in all studies, ranging from 44 to 74%. Of the general models, the SOFA and OSF scores were the most accurate in the prediction of mortality. The MELD score had comparable accuracy to the SOFA in a single published study. 168 In this study, there was a 90% mortality (in ICU or within 6 weeks after discharge) if more than three organ systems were failing at admission. 168, 169 A limitation of several studies in this area is the exclusion of patients undergoing liver transplantation during the period where mortality was determined.
The ideal scoring system is the one that will predict death early enough so that measures can be instituted that will improve survival. Future prospective studies need to evaluate this system, its impact on outcomes in the setting of liver transplantation, and determination of futility.
Relative Adrenal Insufficiency
Cortisol is a stress hormone produced by the hypothalamic-pituitary-adrenal axis in response to physiologic stress and critical illness. In noncirrhotic patients with septic shock, insufficient cortisol production results in increased mortality 170, 171 and blunted response to vasoconstrictors. 172 The administration of stress dose steroids improves survival and systemic hemodynamics. 173, 174 Similar results have been obtained in critically ill cirrhotic patients with sepsis. Relative adrenal insufficiency, as defined by a blunted rise in the serum cortisol level after corticotrophin administration, occurs in 52% of these patients 175 ( Fig. 1) . A diagnosis of adrenal insufficiency correlated with an increase in in-hospital mortality (81% versus 37%), lower cumulative 90-day survival (15% versus 63%), and increased need for vasopressors (73% versus 25%). Independent predictors of adrenal insufficiency on multivariate analysis included serum bilirubin, bacteremia, vasopressor dependency, and mean arterial pressure. 175 
Management
See Fig. 3 for management approaches to prevent bacterial translocation and treat bacterial infections, SIRS/sepsis, and their consequences in patients with cirrhosis.
ANTIBIOTICS
As discussed above, antibiotics are the mainstay of therapy for sepsis in cirrhotic patients. Therapy should be tailored to the presumed source of sepsis. In case of nonresponse, repeat cultures and broadening the spectrum of antibiotics are recommended.
ALBUMIN
The best available evidence would suggest that I.V. albumin be administered in patients with cirrhosis and SIRS/sepsis, particularly in those with any evidence of renal dysfunction and jaundice (i.e., those with acuteon-chronic liver failure). The minimum effective dose has yet to be established, although a recent consensus conference recommended a dose of 1 g/Kg of body weight on the first day (up to a maximum of 100 g), followed by 20 to 40 g/day in the setting of HRS. 138 I.V. albumin may be discontinued if serum albumin rises to levels > 4.5 g/dL and should be withdrawn in case of pulmonary edema. Although conflicting data have been published regarding the safety of albumin in critically ill patients, [176] [177] [178] [179] no meaningful conclusions can be drawn from small subgroups of cirrhotic patients in these studies. Albumin should accompany the use of vasoconstrictors.
180,181
VASOCONSTRICTORS HRS is often precipitated by infection. In fact, as mentioned above, a recent consensus conference considered that renal failure that occurs in the setting of ongoing bacterial infection, but in the absence of septic shock, should be considered HRS and treated as such without waiting for complete recovery from the infection. 138 Vasoconstrictors such as terlipressin [180] [181] [182] [183] and octreotide and midodrine 184, 185 all in combination with albumin have demonstrated an improvement in renal function in HRS. Terlipressin administration in a rat model of LPS-induced septic shock resulted in an improvement in arterial hypotension, aortic hyporeactivity to phenylephrine, and iNOS activity.
186 Figure 3 Site of action of different therapies for bacterial translocation, bacterial infections, SIRS/sepsis, and multiorgan failure. SIRS, systemic inflammatory response syndrome; VCs, vasoconstrictors; ECAD, extracorporeal albumin dialysis.
HYDROCORTISONE
In a small uncontrolled study, the administration of I.V. hydrocortisone (50 mg every 6 hours) to patients with relative adrenal insufficiency resulted in hemodynamic improvement, and increased ICU and in-hospital survival rates. 187 Relative adrenal insufficiency was defined by a baseline cortisol concentration of < 35 mg/dL or an increase in plasma cortisol level < 9 mg/dL after the administration of 250 mg of adrenocorticotropin (in patients with baseline cortisol > 35 mg/dL). However, indiscriminate steroid treatment is not without caution as 2/25 patients treated with hydrocortisone developed invasive fungal infections. In addition, this uncontrolled study requires prospective validation.
LIVER SUPPORT SYSTEMS
The role of liver support systems in the setting of cirrhotic patients with sepsis needs further evaluation as existing data are limited. Ideally, these systems should improve liver function, ameliorate circulatory abnormalities, and eliminate toxins such as ammonia. Extracorporeal albumin dialysis (ECAD) allows the removal of albumin-bound substances such as endotoxin, cytokines, and NO. 188 A recent study in 19 patients with ''decompensated cirrhosis and progressive end-stage liver failure'' showed a mild but significant improvement in systemic hemodynamics with ECAD. 189 A meta-analysis of four randomized trials of ECAD in 67 patients with severe liver failure failed to identify any survival benefit with ECAD compared with standard therapy. 190 Another case series suggested an increased rate of bleeding complications in patients with postoperative hepatic failure and septic multiorgan dysfunction on ECAD. 191 Ongoing multicenter randomized controlled trials using ECAD should help to clarify the safety and efficacy of this device.
SUMMARY
Bacterial infections are an important cause of morbidity and mortality in cirrhotic patients due to their relative immunocompromised state. BT plays a major role in the pathogenesis of infections and in the hyperdynamic circulatory state of cirrhosis. Hemodynamic alterations worsen with the development of overt infection and can progress to severe sepsis and septic shock. Endotoxin, cytokines, and NO are key elements in the pathogenesis of circulatory abnormalities in cirrhosis and sepsis. Early diagnosis and prompt treatment of spontaneous bacterial peritonitis and other infections can significantly reduce morbidity and improve survival, particularly when associated with I.V. albumin in patients with a high risk of developing renal failure. Antibiotic prophylaxis is indicated in patients admitted with GI hemorrhage (short term) and in those who have recovered from an episode of SBP. A selected group of patients with low ascites protein may benefit from antibiotic prophylaxis. Since the widespread use of antibiotic prophylaxis will lead to antimicrobial resistance, it will be important to develop nonantibiotic measures to inhibit BT and infections. Bacterial infection can lead to a systemic inflammatory response and multisystem organ dysfunction including circulatory dysfunction, renal failure, and death. In these patients treatment is mainly directed at treating the infection and circulatory abnormalities through the use of antibiotics, vasoconstrictors, and albumin. Hydrocortisone and liver support devices require further investigation. As critically ill septic cirrhotic patients have a poor prognosis and as resources are not unlimited, it will be important to use prognostic models to better identify when further care is futile as well as identify optimal timing and outcomes of liver transplantation. 
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